Effectiveness of combination with eribulin in third line of chemotherapy for triple negative breast cancer (case report)

2021 ◽  
Vol 1 (31) ◽  
pp. 20-24
Author(s):  
M. V. Kalugin ◽  
K. A. Ivanova ◽  
E. I. Borisova ◽  
S. S. Nakhapetyan ◽  
S. L. Gutorov
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Metastatic Breast ◽  
Breast Cancer Case ◽  
Cancer Case ◽  
Antitumor Action ◽  
Illustrative Case ◽  
Development Of Resistance ◽  
Triple Negative Phenotype

In most cases triple negative breast cancer is characterized by an aggressive course of disease and early development of resistance to chemotherapy. Thereafter, the late-line treatment choice, usually after anthracyclines and taxanes, is problematic due to the limited amount of effective and low-toxic cytostatics. In our opinion, in this situation the use of eribulin which possesses unique antitumor action mechanisms is a good option. An illustrative case of a pronounced antitumor effect of eribulin in metastatic breast cancer with triple negative phenotype resistant to previous lines of chemotherapy is presented.

Experience with eribulin in triple-negative metastatic breast cancer: case studies

2018 ◽  
Vol 14 (7s) ◽  
pp. 13-20 ◽  
Author(s):  
Maria Isabel Gallegos Sancho ◽  
Raúl Márquez-Vázquez ◽  
Alfonso Sánchez-Muñoz
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Studies ◽  
Triple Negative ◽  
Metastatic Breast ◽  
Breast Cancer Case ◽  
Cancer Case

scholarly journals CTCs‐derived xenograft development in a triple negative breast cancer case

2018 ◽  
Author(s):  
Tais Pereira‐Veiga ◽  
Manuel Abreu ◽  
Diego Robledo ◽  
Xavier Matias‐Guiu ◽  
María Santacana ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Case ◽  
Cancer Case

scholarly journals Use of electrochemotherapy in a voluminous chest wall recurrence of triple-negative breast cancer: case report

2020 ◽  
Vol 4 ◽  
pp. 30-30
Author(s):  
Margherita Koleva Radica ◽  
Nicolò Fabbri ◽  
Giorgia Sant’Andrea ◽  
Simona Bonazza ◽  
Antonio Stefanelli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Chest Wall ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Case ◽  
Cancer Case ◽  
Chest Wall Recurrence

scholarly journals Orbital Metastasis from Triple-Negative Breast Cancer: Case Report and Literature Review

2020 ◽  
Vol 13 (2) ◽  
pp. 1042-1046
Author(s):  
Kamal El Bakraoui ◽  
Badr El Morabit
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Hormone Receptors ◽  
Triple Negative ◽  
Palliative Radiotherapy ◽  
Breast Cancer Case ◽  
Cancer Case ◽  
Orbital Metastasis ◽  
Orbital Metastases ◽  
Good Partial Response

Orbital metastases are rare. Breast cancer represents the first etiology to be evoked in carcinomas. We report a rare case of a young 43-year-old patient who developed significant orbital metastasis 2 months after the end of adjuvant treatment for triple-negative breast cancer. Good partial response was shown with an improvement of symptoms under chemotherapy (docetaxel combined with carboplatin), zoledronic acid and palliative radiotherapy. The patient quickly progressed in the pulmonary, hepatic and lymph nodes with mucocutaneous jaundice related to hepatic dysfunction after which she died within 20 days. Different etiologies are responsible for the orbital tumor syndrome. This orbital metastasis may constitute an inaugural mode of expression of the tumor affection. The frequency of metastases of breast cancer overexpressing estrogen receptor can be explained biologically by the presence of estrogen receptors in hormone acting as target choroid tissue steroids for lacrimal secretion. On the other hand, in triple-negative breast cancer, since the hormone receptors are negative, the pathophysiology of these orbital metastases remains unknown. At this stage, the treatment remains palliative, including radiotherapy, chemotherapy, and bisphosphonates, and the prognosis is grim.

scholarly journals Selection of aptamers against triple negative breast cancer cells using high throughput sequencing

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Débora Ferreira ◽  
Joaquim Barbosa ◽  
Diana A. Sousa ◽  
Cátia Silva ◽  
Luís D. R. Melo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Throughput ◽  
Triple Negative Breast Cancer ◽  
High Throughput Sequencing ◽  
Triple Negative ◽  
Metastatic Breast ◽  
Target Cells ◽  
Cancer Tissue ◽  
Surface Receptors

AbstractTriple-negative breast cancer is the most aggressive subtype of invasive breast cancer with a poor prognosis and no approved targeted therapy. Hence, the identification of new and specific ligands is essential to develop novel targeted therapies. In this study, we aimed to identify new aptamers that bind to highly metastatic breast cancer MDA-MB-231 cells using the cell-SELEX technology aided by high throughput sequencing. After 8 cycles of selection, the aptamer pool was sequenced and the 25 most frequent sequences were aligned for homology within their variable core region, plotted according to their free energy and the key nucleotides possibly involved in the target binding site were analyzed. Two aptamer candidates, Apt1 and Apt2, binding specifically to the target cells with $$K_{d}$$ K d values of 44.3 ± 13.3 nM and 17.7 ± 2.7 nM, respectively, were further validated. The binding analysis clearly showed their specificity to MDA-MB-231 cells and suggested the targeting of cell surface receptors. Additionally, Apt2 revealed no toxicity in vitro and showed potential translational application due to its affinity to breast cancer tissue sections. Overall, the results suggest that Apt2 is a promising candidate to be used in triple-negative breast cancer treatment and/or diagnosis.

scholarly journals The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion

Oncogene ◽  
2021 ◽  
Author(s):  
Qiuping Xu ◽  
Jingwei Zhang ◽  
Brian A. Telfer ◽  
Hao Zhang ◽  
Nisha Ali ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Protein Kinase ◽  
Tumor Growth ◽  
Focal Adhesion ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Metastatic Breast ◽  
Adhesion Protein ◽  
Focal Adhesion Protein

AbstractThere is overwhelming clinical evidence that the extracellular-regulated protein kinase 5 (ERK5) is significantly dysregulated in human breast cancer. However, there is no definite understanding of the requirement of ERK5 in tumor growth and metastasis due to very limited characterization of the pathway in disease models. In this study, we report that a high level of ERK5 is a predictive marker of metastatic breast cancer. Mechanistically, our in vitro data revealed that ERK5 was critical for maintaining the invasive capability of triple-negative breast cancer (TNBC) cells through focal adhesion protein kinase (FAK) activation. Specifically, we found that phosphorylation of FAK at Tyr397 was controlled by a kinase-independent function of ERK5. Accordingly, silencing ERK5 in mammary tumor grafts impaired FAK phosphorylation at Tyr397 and suppressed TNBC cell metastasis to the lung without preventing tumor growth. Collectively, these results establish a functional relationship between ERK5 and FAK signaling in promoting malignancy. Thus, targeting the oncogenic ERK5-FAK axis represents a promising therapeutic strategy for breast cancer exhibiting aggressive clinical behavior.

scholarly journals How shall we treat locally advanced triple negative breast cancer?

F1000Research ◽  
2020 ◽  
Vol 8 ◽  
pp. 1649
Author(s):  
Paulo Luz ◽  
David Dias ◽  
Ana Fortuna ◽  
Luis Bretes ◽  
Beatriz Gosalbez
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Locally Advanced ◽  
Surrogate Marker ◽  
Metastatic Breast ◽  
Complete Response ◽  
Number Of Patients ◽  
Her 2 ◽  
Near Future

Triple negative breast cancer (TNBC) has been shown to respond to neoadjuvant chemotherapy (NACT). It has been established that achieving pathological complete response (pCR) for certain aggressive subtypes of breast cancer, including HER-2 (over-expressed) and TNBC, provides an important surrogate marker for predicting long-term clinical response and survival outcomes. How to increase the number of patients that achieve pCR remains challenging. Platinum-based NACT seems to be part of the solution and capecitabine, an active drug in metastatic breast cancer, but not a standard one in earlier stages may have found its place in the adjuvant setting. In the near future immunotherapy can play a role in early TNBC

scholarly journals Antiangiogenic therapy for breast cancer with triple negative phenotype

2021 ◽  
Vol 23 (1) ◽  
pp. 88-92
Author(s):  
Inna P. Ganshina ◽  
Kristina A. Ivanova ◽  
Olga O. Gordeeva ◽  
Aleksandr V. Arkhipov ◽  
Liudmila G. Zhukova
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Malignant Tumors ◽  
Antiangiogenic Therapy ◽  
Treatment Strategies ◽  
Her 2 ◽  
Triple Negative Phenotype ◽  
The Impact ◽  
Negative Phenotype

Triple-negative breast cancer is 1024% of all cases of breast cancer and is characterized by the absence of estrogen, progesterone, and HER-2 receptors in the tumor. The therapy of this illness is a difficult clinical case. In contrast to hormone-positive and HER-2-positive phenotypes, in which we successfully use targeted drugs (antiestrogens and anti-HER-2 drugs), for triple-negative breast cancer we have not had such targets for a long time. Thus, despite the impressive results of immunotherapy of triple-negative breast cancer, there remains a fairly large group of patients with negative PD-L1 status, for whom it is necessary to develop other treatment strategies. One of the approaches in the treatment of malignant tumors includes not the impact on tumor cells, but the process of angiogenesis. Antiangiogenic drugs have positively proven themselves in the treatment of a large number of malignant tumors but are underestimated for breast cancer (including triple-negative phenotype). The use of bevacizumab in combinations with cytostatic drugs in breast cancer therapy (including triple-negative breast cancer) has been studied in a large number of clinical trials but was undeservedly forgotten in some countries due to the revoked FDA registration. This review presents the role of bevacizumab in the treatment of patients with triple-negative breast cancer and suggests the conditions when the administration of this drug is justified and leads to better results.

Sign in / Sign up

Export Citation Format

Share Document